[Treatment of hyperandrogenic manifestations in polycystic ovary syndrome]

[Treatment of hyperandrogenic manifestations in polycystic ovary syndrome] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Treatment of hyperandrogenic manifestations in polycystic ovary syndrome] Abstract Text:

Etiopathogenesis of the polycystic ovarian disease is not clarified. Therefore, optimum therapy of hyperandrogenic syndromes, menstrual and fertility disorders pose a difficult problem. Sequential therapy with estrogens and progestagens is of value in young women, who are not planning to conceive in order to reduce hirsutism and regulate menses. A reduction of hirsutism, acne and seborrhea is produced within 3 months. However, cessation of the treatment produces the symptoms of excessive androgen production. Another method is therapy with antiandrogens, especially cyproterone acetate. This drug inhibits androgens biosynthesis and has also peripheral activity. Spironolactone is another antiandrogen frequently used, but it is known as a primarily diuretic agent. It acts primarily at the androgen receptor sites. Other antiandrogens such as ketoconazole and flutamide are used less frequently. It has been shown, that cimetidine--known H2 receptor inhibitor--also decreases the symptoms of hyperandrogenism. However, cimetidine has not been used for the treatment of polycystic ovarian disease. In cases of enzymatic defects in adrenocortical steroido-synthesis glucocorticoids are used, mainly low doses of triamcinolone and dexamethasone. Other therapies are preferred in case of polycystic ovarian disease in women, who want to conceive. Clomiphene citrate and gonadotropins, mainly FSH, are used to induce ovulation. If pharmacotherapy does not produce ovulation, wedge resection of the ovaries must be performed.

[Treatment of hyperandrogenic manifestations in polycystic ovary syndrome] Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

[Treatment of hyperandrogenic manifestations in polycystic ovary syndrome] Journal Published:

PUBLICATION TYPE: Review

Journal: Polski tygodnik lekarski (Warsaw, Poland : 1960)

VOLUME: 48

Page Numbers: 620-3

Journal Abbreviation: Pol Tyg Lek

ISSN: 0032-3756

DAY: 20

MONTH: 06

YEAR: 2008

[Treatment of hyperandrogenic manifestations in polycystic ovary syndrome] Information

Number of References: 46

LANGUAGE: pol

NlmUniqueID: 9705468

[Treatment of hyperandrogenic manifestations in polycystic ovary syndrome] Keywords Mesh Terms:

KEYWORDS: Polycystic Ovary Syndrome

MESH TERMS: complications

Chemical & Substance for Abstract: [Treatment of hyperandrogenic manifestations in polycystic ovary syndrome] Information

Substance Name: Hormones

Registry Number: 0

Grant and Affiliation Information for [Treatment of hyperandrogenic manifestations in polycystic ovary syndrome]

AFFILIATION: Katedry i Kliniki Endokrynologii AM, Wroc?awiu.

Country: POLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pol Tyg Lek

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Treatment of hyperandrogenic manifestations in polycystic ovary syndrome Related Publications

• Comparison of the in vitro hemolytic effects produced by alkoxyacetic acids on human and rat erythrocytes.
• Fingered growth in channel geometry: A Loewner-equation approach.
• [Effect of disorders of thyroid function on phenazone pharmacokinetics]
• [Occupational diseases in Poland, 2006]
• [Occupational diseases in Poland, 2007]
• [Pharmacokinetics of phenazone as an indicator of the metabolic capacity of the liver in patients with hyperthyroidism]
• [Protein, total lipid and fatty acid content in human milk and milk substitutes]
• [Treatment of hyperandrogenic manifestations in polycystic ovary syndrome]
• [Werner's syndrome]
• [Work-related stress and the Conservation of Resources Theory by Stevan Hobfoll]